A randomized, open-label study of PEGASYS plus 2 different doses of ribavirin on sustained virological response in patients with chronic hepatitis C viral infection, genotype 2 or 3.
Phase of Trial: Phase IV
Latest Information Update: 14 Jul 2016
At a glance
- Drugs Ribavirin (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 09 Dec 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
- 26 Jun 2006 New trial record.